Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06907017

CorWave LVAS FIH Study

Led by CorWave · Updated on 2026-02-09

20

Participants Needed

2

Research Sites

155 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients.

CONDITIONS

Official Title

CorWave LVAS FIH Study

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subject or legal representative has signed Informed Consent Form
  • Age greater than 18 and less than 75 years old
  • Body Surface Area (BSA) of at least 1.2 m2
  • Left Ventricular Ejection Fraction (LVEF) of 35% or less
  • Inotrope dependent OR Cardiac Index (CI) less than 2.2 L/min/m2 while not on inotropes and meeting one of the following:
    • On Guideline Directed Medical Therapy (GDMT) for at least 45 out of the last 60 days without response
    • Advanced heart failure (Class III or IV for at least 14 days) with support from short term mechanical circulatory support up to 7 days
  • Females of childbearing age must agree to use adequate contraception
  • Patient must be eligible for heart transplantation
Not Eligible

You will not qualify if you...

  • Heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or restrictive cardiomyopathy
  • Technical obstacles posing high surgical risk per Investigator
  • Ongoing mechanical circulatory support other than IABP or micro axial pumps
  • INTERMACS Class I patients
  • Patient on a ventilator
  • Pregnant or breastfeeding
  • Presence of a mechanical aortic valve not planned for conversion to bioprosthesis at LVAD implant
  • History of any organ transplant
  • Platelet count below 100,000/µl
  • Psychiatric disease, illicit drug use, irreversible cognitive dysfunction, or psychosocial issues impairing compliance
  • History of untreated abdominal aortic aneurysm greater than 5 cm within 6 months
  • Active, uncontrolled infection
  • Intolerance to anticoagulant or antiplatelet therapies or required peri/post-operative therapy
  • Severe end organ dysfunction or failure signs such as:
    • INR 2.0 or higher not due to anticoagulation therapy
    • Total bilirubin above 43 µmol/L (2.5 mg/dL), liver function tests > 3 times normal, serum albumin below 3.5 g/dl, shock liver, or liver cirrhosis
    • Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease with FEV1 less than 50%, total FEV1 below 1000 mL, and DLCO less than 50% predicted
    • Fixed pulmonary hypertension with PVR 8 Wood units or higher unresponsive to treatment
  • Stroke within 90 days prior or cerebrovascular disease with significant carotid stenosis
  • Serum creatinine 221 µmol/L (2.5 mg/dL) or higher or need for chronic renal replacement therapy
  • Ongoing malnutrition with over 5% weight loss in 30 days, low prealbumin, or poor nutritional assessment score
  • Poorly controlled diabetes or hemoglobin A1c over 8.5%
  • Significant peripheral vascular disease with rest pain or ulcers
  • Severe aortic insufficiency without planned correction during implant
  • Planned Bi-VAD support before enrollment
  • Known hypo- or hypercoagulable states like disseminated intravascular coagulation or heparin induced thrombocytopenia
  • Participation in other clinical studies affecting results
  • Conditions other than heart failure limiting survival to less than 12 months
  • Acute myocardial infarction within 14 days of implant
  • Pulmonary embolus within 6 weeks of implant
  • Unwillingness or inability to comply with trial requirements

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

St Vincent's Hospital Sydney

Sydney, New South Wales, Australia, 2010

Actively Recruiting

2

Bayside Health

Melbourne, Victoria, Australia, 3004

Actively Recruiting

Loading map...

Research Team

G

Gabriella Giaquinta

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

CorWave LVAS FIH Study | DecenTrialz